Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4349128 | 0.82 | NPY5R (0.43) | GAACYP3A4TSHRRECQLALDH1A1 | |
| SCHEMBL4770454 | 0.80 | CNR2 (0.49) | CNR2TSHRALDH1A1L3MBTL1RORC | |
| SCHEMBL3192672 | 0.79 | CNR2 (0.65) | CNR2L3MBTL1RORCCA1CA2 | |
| SCHEMBL13480854 | 0.79 | RORC (0.46) | CNR2GAARECQLRORCMAPT | |
| SCHEMBL4437877 | 0.78 | CNR2 (0.44) | CNR2TSHRALDH1A1TDP1CA1 | |
| SCHEMBL3442462 | 0.77 | GAA (0.48) | GAACYP3A4TSHRRECQLALDH1A1 | |
| SCHEMBL514597 | 0.76 | RECQL (0.48) | GAACYP3A4TSHRRECQLALDH1A1 | |
| SCHEMBL30009960 | 0.76 | TSHR (0.41) | GAACYP3A4TSHRRECQLALDH1A1 | |
| SCHEMBL14039773 | 0.76 | CNR2 (0.45) | CNR2ALDH1A1MAPK1RORCLMNA | |
| SCHEMBL2997991 | 0.74 | LOXL2 (0.47) | CNR2TSHRMAPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137164-B1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-08-26 | — | — | EP | disclosed |
| EP-2137164-B1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-08-26 | — | — | EP | disclosed |
| US-8389521-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-03-05 | — | — | US | disclosed |
| US-8389521-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-03-05 | — | — | US | disclosed |
| US-8389521-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-03-05 | — | — | US | disclosed |
| US-20100184780-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184780-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184780-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| EP-2137164-A1 | INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20080275063-A1 | C-{4-[6-(2-Ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-N-propyl-methanesulfonamide; antiinflammatories, antiproliferatives, analgesics; cardiovascular disorders, neurodegenerative diseases; immunotherapy | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275063-A1 | C-{4-[6-(2-Ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-N-propyl-methanesulfonamide; antiinflammatories, antiproliferatives, analgesics; cardiovascular disorders, neurodegenerative diseases; immunotherapy | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275063-A1 | C-{4-[6-(2-Ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-N-propyl-methanesulfonamide; antiinflammatories, antiproliferatives, analgesics; cardiovascular disorders, neurodegenerative diseases; immunotherapy | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| WO-2008129069-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008129069-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184780-A1 | INHIBITORS OF PROTEIN KINASES | CDK5, CDK5R1, CDK1 | CNR2 1953/4885GAA 2845/4885CYP3A4 4306/4885 |
| US-20080275063-A1 | C-{4-[6-(2-Ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-N-propyl-methanesulfonamide; antiinflammatories, antiproliferatives, analgesics; cardiovascular disorders, neurodegenerative diseases; immunotherapy | CDK5, CDK5R1, CDK4 | CNR2 686/4885GAA 3221/4885CYP3A4 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.